Intelligent Bio Solutions Inc. Share Price

Equities

INBS

US36151G6008

Biotechnology & Medical Research

End-of-day quote Nasdaq 03:30:00 30/04/2024 am IST 5-day change 1st Jan Change
2.69 USD -3.93% Intraday chart for Intelligent Bio Solutions Inc. -3.24% -33.66%
Sales 2024 * 4.18M 349M Sales 2025 * 9.43M 787M Capitalization 7.65M 638M
Net income 2024 * -8M -668M Net income 2025 * -6M -501M EV / Sales 2024 * 1.83 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.81 x
P/E ratio 2024 *
-0.73 x
P/E ratio 2025 *
-0.78 x
Employees 51
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.4%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.93%
1 week-3.24%
1 month-36.26%
3 months+7.60%
6 months+3.64%
Current year-33.66%
More quotes
1 week
2.45
Extreme 2.45
2.90
1 month
2.45
Extreme 2.45
4.11
Current year
2.28
Extreme 2.28
11.70
1 year
2.28
Extreme 2.28
49.20
3 years
2.28
Extreme 2.28
1 226.40
5 years
2.28
Extreme 2.28
3 417.58
10 years
2.28
Extreme 2.28
3 417.58
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 01/17/01
Chairman 67 01/20/01
Director of Finance/CFO 63 01/19/01
Members of the board TitleAgeSince
Director/Board Member 86 01/20/01
Chief Executive Officer 56 01/17/01
Director/Board Member 54 01/18/01
More insiders
Date Price Change Volume
30/24/30 2.69 -3.93% 30,168
29/24/29 2.8 +4.09% 40,400
26/24/26 2.69 +8.91% 40,699
25/24/25 2.47 -3.89% 52,608
24/24/24 2.57 -7.55% 51,711

End-of-day quote Nasdaq, April 30, 2024

More quotes
Intelligent Bio Solutions Inc. is a life sciences company. The Company is engaged in developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It operates through two segments, namely Commercially available Intelligent Fingerprinting Products (IFPG) and Development Stage Saliva Glucose Biosensor Platform (SGBP). Its product portfolio includes a portable drug screening system that works by analyzing fingerprint sweat using a one-time cartridge and portable handheld reader and also includes a development stage range of biosensor- based Point of Care diagnostic tests (POCT) that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology. Its product candidate is the Saliva Glucose Biosensor (SGB), a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. Its Biosensor Platform helps to detect multiple biological analytes.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.8 USD
Average target price
42 USD
Spread / Average Target
+1,400.00%
Consensus